GSK Adds 516,000 Shares to Treasury in Ongoing Buyback

GlaxoSmithKline ( (GB:GSK) ) just unveiled an announcement.

GSK has repurchased 516,000 ordinary shares on 9 March 2026 via BNP Paribas as part of its ongoing share buyback programme, paying a volume-weighted average price of 2,028.51p per share and placing the stock into treasury, a move that incrementally boosts earnings per share for remaining investors. Since the programme’s February launch the company has bought 7.67 million shares, taking treasury holdings to about 247.6 million shares, or 6.08% of voting rights, and leaving 4.07 billion shares in issue for regulatory disclosure calculations under UK rules.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.

The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GSK plc is a global biopharmaceutical company focused on developing and commercializing vaccines, specialty medicines and general medicines. Listed in London, it targets infectious diseases, HIV, respiratory and oncology markets, with an emphasis on scaled R&D and returns to shareholders through dividends and share buybacks.

Average Trading Volume: 9,045,169

Technical Sentiment Signal: Buy

Current Market Cap: £81.97B

See more data about GSK stock on TipRanks’ Stock Analysis page.